GDF5 Polymorphism associated with osteoarthritis: risk for rheumatoid arthritis. (vol 67, pg 1352, 2008)

被引：0

|

作者：

Martinez, A.

Varade, J.

Lamas, J. R.

机构：

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2009年 / 68卷 / 06期

关键词：

D O I：

10.1136/ard.2007.085050.corr1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1080 / 1080

页数：1

相关论文

共 34 条

[31] Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel (vol 174, pg 1715, 2006)
Suh, JW
Koo, BK
Zhang, SY
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 175 (01) : 64 - 64
[32] Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D, RAQoL, and HAQ in patients with rheumatoid arthritis (vol 35, pg 1528, 2008)
Linde, L.
sorensen, J.
Ostergaard, M.
Horslev-Petersen, K.
JOURNAL OF RHEUMATOLOGY, 2008, 35 (08) : 1688 - 1688
[33] The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden (vol 9, pg R56, 2007)
Kokkonen, Heidi
Johansson, Martin
Innala, Lena
Jidell, Erik
Rantapaa-Dahlqvist, Solbritt
ARTHRITIS RESEARCH & THERAPY, 2007, 9 (05)
[34] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008)
Emery, P.
Keystone, E.
Tony, H. P.
Cantagrel, A.
van Vollenhoven, R.
Sanchez, A.
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (02) : 296 - 296

← 1 2 3 4 →